ClinicalTrials.gg
CompletedNCT04154943Updated Dec 23, 2025Results posted

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

A Phase 2 interventional study of Cemiplimab in Cutaneous Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.

The secondary objectives of the study are:

  • To evaluate the efficacy of neoadjuvant cemiplimab on measures of disease response, including:
  • Major pathologic response (mPR) rate per independent central pathology review
  • pCR rate and mPR rate per local pathology review
  • ORR prior to surgery, according to local assessment using RECIST 1.1
  • To evaluate the efficacy of neoadjuvant cemiplimab on event free survival (EFS), disease free survival (DFS), and overall survival (OS)
  • To evaluate the safety profile of neoadjuvant cemiplimab
  • To assess change in surgical plan (ablative and reconstructive procedures) from the screening period to definitive surgery, both according to investigator review and independent surgical expert review
  • To assess change in post-surgical management plan (radiation, chemoradiation, or observation) from the screening period to post-surgery pathology review, both according to investigator review and independent surgical expert review
02

Conditions studied

  • Cutaneous Squamous Cell Carcinoma

Keywords

  • CSCC
  • Stage II
  • Stage III
  • Stage IV
  • CSCC of Head/neck
  • CSCC of Extremity
  • CSCC of Trunk
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Stage II to IV (M0) CSCC, for which surgery would be recommended in routine clinical practice. For stage II patients, lesion must be ≥3 cm at the longest diameter.
  • At least 1 lesion that is measurable by 1.1
  • (ECOG) performance status of 0 or 1
  • Adequate organ, bone marrow function, and hepatic function as defined in the protocol

Key Exclusion Criteria

  • Solid within 5 years of the projected enrollment date, or hematologic malignancy (including chronic lymphocytic leukemia [CLL]) at any time
  • Distant disease (M1), visceral and/or distant nodal
  • Prior radiation therapy for CSCC
  • Patients with a condition requiring therapy (>10 mg prednisone/day or equivalent) within 14 days of the first dose of study drug.
  • Patients with active, known, or suspected disease that has required systemic therapy within 5 years of the projected enrollment date.
  • History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
  • Uncontrolled infection with (HIV), or virus (HBV or HCV) infection; or diagnosis of immunodeficiency
  • Active tuberculosis

NOTE: Other protocol-defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Cemiplimab

    Will receive IV infusion Q3W

    Drug: Cemiplimab

Interventions

  • Intravenous (IV) infusion every 3 weeks (Q3W)

    Also known as: REGN2810, Libtayo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Number of Participants With Major Pathologic Response (mPR) as Assessed by Independent Central Pathology Review

    Time frame: Up to 12 Weeks

  2. Number of Participants With Pathologic Complete Response (pCR) as Assessed by Local Pathology Review

    Time frame: Up to 12 weeks

  3. Number of Participants With Major Pathologic Response (mPR) as Assessed by Local Pathology Review

    Time frame: Up to 12 Weeks

  4. Percentage of Participants With Objective Response Rate (ORR) Prior to Surgery, According to Investigator Assessment Using RECIST 1.1

    Time frame: Up to 12 Weeks

  5. Number of Participants With Planned and Actual Surgery After Neoadjuvant Cemiplimab

    Time frame: Up to 12 Weeks

  6. Number of Participants With Planned and Actual Post-Surgical Management

    Time frame: Up to 14 Weeks

  7. Event Free Survival (EFS)

    Time frame: Up to 50 Months

  8. Disease Free Survival (DFS)

    Time frame: Up to 47 Months

  9. Overall Survival (OS)

    Time frame: Up to 50 Months

  10. Incidence of Adverse Events (AEs)

    Time frame: Up to 52 Months

  11. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 52 Months

  12. Incidence of Deaths

    Time frame: Up to 52 Months

  13. Incidence of Laboratory Abnormalities

    Time frame: Up to 52 Months

07

Results

Posted Feb 8, 2023

Participant flow

Participant flow — Overall Study
MilestoneCemiplimab 350mg Q3W
Started79
Completed0
Not completed79
Withdrew: Study ongoing68
Withdrew: Lost to follow-up1
Withdrew: Decision by the investigator1
Withdrew: Death5
Withdrew: Withdrawal by subject4

Outcome measures

SecondaryNumber of Participants With Major Pathologic Response (mPR) as Assessed by Independent Central Pathology Review
Time frame:
Up to 12 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Major Pathologic Response (mPR) as Assessed by Independent Central Pathology Review
ParticipantsCemiplimab 350mg Q3W
Number of Participants With Major Pathologic Response (mPR) as Assessed by Independent Central Pathology Review10
PrimaryNumber of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review
Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review
ParticipantsCemiplimab 350mg Q3W
Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review40
SecondaryNumber of Participants With Pathologic Complete Response (pCR) as Assessed by Local Pathology Review
Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Pathologic Complete Response (pCR) as Assessed by Local Pathology Review
ParticipantsCemiplimab 350mg Q3W
Number of Participants With Pathologic Complete Response (pCR) as Assessed by Local Pathology Review42
SecondaryNumber of Participants With Major Pathologic Response (mPR) as Assessed by Local Pathology Review
Time frame:
Up to 12 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Major Pathologic Response (mPR) as Assessed by Local Pathology Review
ParticipantsCemiplimab 350mg Q3W
Number of Participants With Major Pathologic Response (mPR) as Assessed by Local Pathology Review10
SecondaryPercentage of Participants With Objective Response Rate (ORR) Prior to Surgery, According to Investigator Assessment Using RECIST 1.1
Time frame:
Up to 12 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response Rate (ORR) Prior to Surgery, According to Investigator Assessment Using RECIST 1.1
Percentage of ParticipantsCemiplimab 350mg Q3W
Percentage of Participants With Objective Response Rate (ORR) Prior to Surgery, According to Investigator Assessment Using RECIST 1.168.4 (56.9 to 78.4)
SecondaryNumber of Participants With Planned and Actual Surgery After Neoadjuvant Cemiplimab
Time frame:
Up to 12 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Planned and Actual Surgery After Neoadjuvant Cemiplimab
ParticipantsCemiplimab 350mg Q3W
Participants with Planned Mohs Surgery2
Participants with Actual Mohs Surgery2
Participants with Planned Non-Mohs Surgery77
Participants with Actual Non-Mohs Surgery68
SecondaryNumber of Participants With Planned and Actual Post-Surgical Management
Time frame:
Up to 14 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Planned and Actual Post-Surgical Management
ParticipantsCemiplimab 350mg Q3W
Planned radiation therapy after surgery47
Actual radiation therapy after surgery17
SecondaryEvent Free Survival (EFS)
Time frame:
Up to 50 Months

Results for this outcome have not been posted.

SecondaryDisease Free Survival (DFS)
Time frame:
Up to 47 Months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
Up to 50 Months

Results for this outcome have not been posted.

SecondaryIncidence of Adverse Events (AEs)
Time frame:
Up to 52 Months

Results for this outcome have not been posted.

SecondaryIncidence of Serious Adverse Events (SAEs)
Time frame:
Up to 52 Months

Results for this outcome have not been posted.

SecondaryIncidence of Deaths
Time frame:
Up to 52 Months

Results for this outcome have not been posted.

SecondaryIncidence of Laboratory Abnormalities
Time frame:
Up to 52 Months

Results for this outcome have not been posted.

Adverse events

Collected over From first dose to the end of treatment period (Week 25) up to 01-DEC-2021 Data cut-off. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cemiplimab 350 mg Q3W6/79 (7.6%)15/79 (19%)60/79 (75.9%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventCemiplimab 350 mg Q3W
Myocardial infarctionCardiac disorders2/79
Acute myocardial infarctionCardiac disorders1/79
Atrial flutterCardiac disorders1/79
Cardiac failure congestiveCardiac disorders1/79
CardiomyopathyCardiac disorders1/79
ColitisGastrointestinal disorders1/79
DysphagiaGastrointestinal disorders1/79
CholelithiasisHepatobiliary disorders1/79
Immune-mediated hepatitisHepatobiliary disorders1/79
COVID-19 pneumoniaInfections and infestations1/79
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCemiplimab 350 mg Q3W
FatigueGeneral disorders24/79
DiarrhoeaGastrointestinal disorders12/79
NauseaGastrointestinal disorders12/79
Rash maculo-papularSkin and subcutaneous tissue disorders11/79
ConstipationGastrointestinal disorders10/79
PruritusSkin and subcutaneous tissue disorders8/79
HypothyroidismEndocrine disorders7/79
Decreased appetiteMetabolism and nutrition disorders7/79
DizzinessNervous system disorders6/79
RashSkin and subcutaneous tissue disorders5/79

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cemiplimab 350mg Q3W
Mean71.5 ± 11.3
Age, Customized
Age, Customized(Participants)Cemiplimab 350mg Q3W
17 years and under0
18 to 64 years18
65 to 84 years54
85 years and over7
Sex: Female, Male
Sex: Female, Male(Participants)Cemiplimab 350mg Q3W
Female12
Male67
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cemiplimab 350mg Q3W
White69
Asian1
Other1
Unknown / Not Reported8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cemiplimab 350mg Q3W
Not Hispanic or Latino74
Unknown/Not Reported5
08

Study locations

22 sites
  • Regeneron Study Site
    Palo Alto, California 94304, United States
  • Regeneron Study Site
    Washington D.C., District of Columbia 20037, United States
  • Regeneron Study Site
    Miami, Florida 33176, United States
  • Regeneron Study Site
    Tampa, Florida 33612, United States
  • Regeneron Study Site
    Baltimore, Maryland 21231, United States
  • Regeneron Study Site
    Boston, Massachusetts 02114, United States
  • Regeneron Study Site
    Boston, Massachusetts 02215, United States
  • Regeneron Study Site
    Ann Arbor, Michigan 48109, United States
  • Regeneron Study Site
    Omaha, Nebraska 68114, United States
  • Regeneron Study Site
    New York, New York 10065, United States
  • Regeneron Study Site
    Charlotte, North Carolina 28204, United States
  • Regeneron Study Site
    Durham, North Carolina 27710, United States
  • Regeneron Study Site
    Cleveland, Ohio 44195, United States
  • Regeneron Study Site
    Dallas, Texas 75390, United States
  • Regeneron Study Site
    Houston, Texas 77030, United States
  • Regeneron Study Site
    St Leonards, New South Wales 2065, Australia
  • Regeneron Study Site
    Herston, Queensland 4029, Australia
  • Regeneron Study Site
    Melbourne, Victoria 3000, Australia
  • Regeneron Study Site
    Dresden, 01307, Germany
  • Regeneron Study Site
    Essen, 45147, Germany
  • Regeneron Study Site
    Kiel, 24105, Germany
  • Regeneron Study Site
    Tübingen, 72076, Germany
09

References and documents

Publications

  • Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Yoo SY, Mathias M, Han H, Seebach F, Lowy I, Fury MG, Rischin D. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol. 2023 Nov;24(11):1196-1205. doi: 10.1016/S1470-2045(23)00459-X. Epub 2023 Oct 21. PubMed 37875144 ↗
  • Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2022 Oct 27;387(17):1557-1568. doi: 10.1056/NEJMoa2209813. Epub 2022 Sep 12. PubMed 36094839 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Dec 2021, 20 months.

Results were first posted in Feb 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2019
First posted
Nov 7, 2019
StartActual
Mar 10, 2020
Primary completionActual
Dec 1, 2021
CompletionActual
Nov 19, 2025
Results first posted
Feb 8, 2023
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04154943
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Mar 10, 2020
Primary completion
Dec 1, 2021
Completion
Nov 19, 2025
Results posted
Feb 8, 2023
Last update
Dec 23, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion